SOHO 2026: Key Insights in Lymphoma, Myelodysplastic Syndromes, and Chronic Lymphocytic Leukemia

In this video, clinical experts highlight key presentations, clinical trial readouts, and therapeutic updates in hematologic oncology from the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, Listen in as Jasmine M. Zain, MD; David Sallman, MD; and Julie M. Vose, MD, MBA, unpack updates spanning lymphoma, myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL): Secondary Malignancies After CAR T-Cell Therapy: Jasmine M. Zain, MD, an attending physician in the Lymphoma Service at Memorial Sloan Kettering Cancer Center, detailed the incidence, mechanisms, and risk factors of second primary malignancies following CAR T-cell therapy. She also outlined clinical strategies to differentiate retroviral/lentiviral insertional mutagenesis from cumulative genotoxic stress. Targeting NLRP3 Inflammasome in LR-MDS: David Sallman, MD, an associate member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, presented phase 2a results (NCT07052006) for ofirnoflast (HT-6184), a first-in-class oral NEK7 inhibitor. He discussed platelet/neutrophil responses and how an intermittent oral regimen may support quality of life in patients with lower-risk MDS. Evolving Paradigms in CLL: Julie M. Vose, MD, MBA, the George and Peggy Payne Distinguished Chair of Oncology, a professor in the Division of Hematology, and director of the Lymphoma Research Group at the University of Nebraska Medical Center, and co–editor in chief of ONCOLOGY®, shared takeaways on minimal residual disease (MRD) testing as a decision-making tool, time-limited combination regimens, and actionable ways for community oncologists to stay up to date in the field. 00:20 Zain: Secondary Malignancies Key Takeaways 00:58 Zain: Differentiating Between Mutagenesis vs Genotoxic Stress 03:19 Zain: Measuring the Impact of Reduced Cytotoxic Exposure on Secondary Primary Malignancies 04:25 Sallman: Biomarker Data to Support Disease Modification with Ofirnoflast 05:27 Sallman: Comparing Multilineage Activity With Standard Second-Line Therapies 07:14 Sallman: Intermittent Dosing on Optimizing Long-Term Compliance and Quality of Life 09:22 Vose: Overcoming Challenges with CLL Treatment in the Community Setting 10:01 Vose: Elucidating the Readiness of MRD-Guided Treatment 10:48 Vose: Final Remarks/Key Takeaway From SOHO #SOHO2026 #HematologicOncology #Lymphoma #MDS #CLL #CARTcellTherapy #Oncology #CancerNetwork Don't forget to check us out on: YouTube:    / @cancernetwork   X/Twitter: https://x.com/cancernetwrk?lang=en LinkedIn: https://www.linkedin.com/company/canc... Facebook:   / cancer-network-100059801696024   Instagram:   / cancernetwrk